| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 150.409 | 192.959 | 241.887 | 282.214 | 277.097 | 333.814 | 327.162 | 422.954 | 496.443 | 509.138 |
| Total Income - EUR | 150.421 | 192.992 | 241.895 | 282.222 | 277.106 | 333.819 | 327.164 | 422.947 | 496.448 | 509.151 |
| Total Expenses - EUR | 133.596 | 167.056 | 216.014 | 260.382 | 246.017 | 298.772 | 292.219 | 403.954 | 468.154 | 467.286 |
| Gross Profit/Loss - EUR | 16.825 | 25.936 | 25.881 | 21.840 | 31.089 | 35.048 | 34.945 | 18.993 | 28.294 | 41.865 |
| Net Profit/Loss - EUR | 14.130 | 21.778 | 23.565 | 19.142 | 28.825 | 32.401 | 32.487 | 16.098 | 23.836 | 35.044 |
| Employees | 2 | 1 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Check the financial reports for the company - Adypharm Lunca Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 61 | 60 | 285 | 280 | 275 | 270 | 264 | 2.541 | 2.247 | 1.956 |
| Current Assets | 72.405 | 74.908 | 104.018 | 119.277 | 97.767 | 155.833 | 152.710 | 173.124 | 188.107 | 198.893 |
| Inventories | 33.793 | 32.711 | 62.175 | 51.508 | 46.506 | 53.182 | 80.846 | 72.030 | 76.317 | 109.646 |
| Receivables | 11.045 | 7.922 | 29.775 | 48.403 | 34.235 | 80.042 | 55.940 | 82.083 | 85.384 | 41.514 |
| Cash | 27.568 | 34.276 | 12.067 | 19.366 | 17.026 | 22.609 | 15.924 | 19.011 | 26.406 | 47.733 |
| Shareholders Funds | 17.964 | 25.574 | 27.478 | 23.122 | 32.956 | 36.454 | 36.452 | 20.076 | 27.803 | 38.989 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 54.502 | 49.394 | 76.825 | 96.435 | 65.086 | 119.649 | 116.521 | 155.588 | 162.551 | 161.860 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Adypharm Lunca Srl